NCT02161510View on ClinicalTrials.gov

Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002)

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

April 30, 2015

Conditions
Hepatitis C
Interventions
DRUG

MK-2248

MK-2248 in once-daily oral doses of 200-≤800 mg for 7 days

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02161510 - Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002) | Biotech Hunter | Biotech Hunter